A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for Human Immunodeficiency Virus-associated tuberculous meningitis: the LASER-TBM trial. Davis, A. G, Wasserman, S., Stek, C., Maxebengula, M., Liang, C J., Stegmann, S., Koekemoer, S., Jackson, A., Kadernani, Y., Bremer, M., Daroowala, R., Aziz, S., Goliath, R., Sai, L. L., Sihoyiya, T., Denti, P., Lai, R. P., Crede, T., Naude, J., Szymanski, P., Vallie, Y., Banderker, I. A., Moosa, M. S, Raubenheimer, P., Candy, S., Offiah, C., Wahl, G., Vorster, I., Maartens, G., Black, J., Meintjes, G. A, & Wilkinson, R. J Clinical Infectious Diseases, 76(8):1412–1422, dec, 2023.
A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for Human Immunodeficiency Virus-associated tuberculous meningitis: the LASER-TBM trial [link]Paper  doi  abstract   bibtex   
Background: Drug regimens which include intensified antibiotics alongside effective anti-inflammatory therapies may improve outcomes in Tuberculous Meningitis (TBM). Safety data on their use in combination and in the context of HIV is needed to inform clinical trial design. Methods: We conducted a phase 2 open-label parallel-design RCT to assess safety of high-dose rifampicin, linezolid and high-dose aspirin in HIV-associated TBM. Participants were randomised (1.4:1:1) to three treatment arms (arm 1, standard of care (SOC); arm 2 SOC + additional rifampicin (up to 35mg/kg/day)) + linezolid 1200mg/day reducing after 28/7 to 600mg/day; arm 3, as per arm 2 + aspirin 1000mg/day) for 56 days, when the primary outcome of adverse events of special interest (AESI) or death was assessed. Results: 52 participants with HIV-associated TBM were randomised. 59% had mild disease (MRC Grade 1) vs 39% (Grade 2) vs 2% (Grade 3). 33% had microbiologically-confirmed TBM; 41% 'possible', 25% 'probable'. AESI or death occurred in 10/16 (63%) (arm 3) vs 4/14 (29%) (arm 2) vs 6/20 (30%) (arm 1) (p=0.083). The cumulative proportion of AESI or death (Kaplan-Meier) demonstrated worse outcomes in arm 3 vs arm 1 (p=0.04), however only one event in arm 3 was attributable to aspirin and was mild. There was no difference in efficacy (modified Rankin scale) at day 56 between arms. Conclusions: High-dose rifampicin and adjunctive linezolid can safely be added to SOC in HIV-associated TBM. Larger studies are required to evaluate whether potential toxicity associated with these interventions, particularly high-dose aspirin, is outweighed by mortality or morbidity benefit.
@article{Davis2022b,
abstract = {Background: Drug regimens which include intensified antibiotics alongside effective anti-inflammatory therapies may improve outcomes in Tuberculous Meningitis (TBM). Safety data on their use in combination and in the context of HIV is needed to inform clinical trial design. Methods: We conducted a phase 2 open-label parallel-design RCT to assess safety of high-dose rifampicin, linezolid and high-dose aspirin in HIV-associated TBM. Participants were randomised (1.4:1:1) to three treatment arms (arm 1, standard of care (SOC); arm 2 SOC + additional rifampicin (up to 35mg/kg/day)) + linezolid 1200mg/day reducing after 28/7 to 600mg/day; arm 3, as per arm 2 + aspirin 1000mg/day) for 56 days, when the primary outcome of adverse events of special interest (AESI) or death was assessed. Results: 52 participants with HIV-associated TBM were randomised. 59{\%} had mild disease (MRC Grade 1) vs 39{\%} (Grade 2) vs 2{\%} (Grade 3). 33{\%} had microbiologically-confirmed TBM; 41{\%} 'possible', 25{\%} 'probable'. AESI or death occurred in 10/16 (63{\%}) (arm 3) vs 4/14 (29{\%}) (arm 2) vs 6/20 (30{\%}) (arm 1) (p=0.083). The cumulative proportion of AESI or death (Kaplan-Meier) demonstrated worse outcomes in arm 3 vs arm 1 (p=0.04), however only one event in arm 3 was attributable to aspirin and was mild. There was no difference in efficacy (modified Rankin scale) at day 56 between arms. Conclusions: High-dose rifampicin and adjunctive linezolid can safely be added to SOC in HIV-associated TBM. Larger studies are required to evaluate whether potential toxicity associated with these interventions, particularly high-dose aspirin, is outweighed by mortality or morbidity benefit.},
author = {Davis, Angharad G and Wasserman, Sean and Stek, Cari and Maxebengula, Mpumi and Liang, C Jason and Stegmann, Stephani and Koekemoer, Sonya and Jackson, Amanda and Kadernani, Yakub and Bremer, Marise and Daroowala, Remy and Aziz, Saalikha and Goliath, Rene and Sai, Louise Lai and Sihoyiya, Thandi and Denti, Paolo and Lai, Rachel PJ and Crede, Thomas and Naude, Jonathan and Szymanski, Patryk and Vallie, Yakoob and Banderker, Ismail Abbas and Moosa, Muhammed S and Raubenheimer, Peter and Candy, Sally and Offiah, Curtis and Wahl, Gerda and Vorster, Isak and Maartens, Gary and Black, John and Meintjes, Graeme A and Wilkinson, Robert J},
doi = {10.1093/CID/CIAC932},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Davis et al. - 2023 - A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or wit.pdf:pdf},
issn = {1058-4838},
journal = {Clinical Infectious Diseases},
keywords = {HIV,OA,Tuberculous meningitis,aspirin,fund{\_}ack,linezolid,original,rifampicin},
mendeley-tags = {OA,fund{\_}ack,original},
month = {dec},
number = {8},
pages = {1412--1422},
pmid = {36482216},
title = {{A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for Human Immunodeficiency Virus-associated tuberculous meningitis: the LASER-TBM trial}},
url = {https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac932/6884164},
volume = {76},
year = {2023}
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021